StockNews.AI
ZVRA
StockNews.AI
174 days

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

1. Zevra Therapeutics will report Q4 and full year 2024 results on Mar. 11, 2025. 2. A conference call will occur at 4:30 p.m. ET the same day. 3. Zevra focuses on therapies for rare diseases with limited treatment options. 4. Forward-looking statements caution against reliance on projections. 5. Replay of the conference call will be available for 90 days.

Earnings
+4.85%Current Return
VS
-1.95%S&P 500
$7.4302/26 09:49 AM EDTEvent Start
$7.7902/27 04:33 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The scheduled conference call may not yield new significant information; past call outcomes have varied without major stock movement.

How important is it?

Upcoming earnings report is crucial for stakeholders; however, past performance suggests tempered expectations.

Why Short Term?

The impact of Q4 results and call insights will primarily affect immediate trading sentiment.

Related Companies

PTCTRARESAGESGMO
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET February 26, 2025 09:46 ET  | Source: Zevra Therapeutics CELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2024 on Tuesday, Mar. 11, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/. To join via telephone, please use the following dial-in information: (800) 245-3047 (United States)+1 (203) 518-9765 (International)Conference ID: ZVRAQ424 A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page of Zevra’s website at https://investors.zevra.com/. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit www.zevra.com or follow us on X and LinkedIn. Caution Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended Sept. 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.  Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@zevra.com  

Related News